Back to News
Market Impact: 0.15
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
Source: marketbeat.com
Healthcare & Biotech
Zai Lab presented early-stage data at the 2026 European Society for Medical Oncology meeting for zoci, its DLL3-targeted antibody-drug conjugate, in first-line extensive-stage small cell lung cancer. The regimen combined zoci with atezolizumab, with or without carboplatin; the article provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ZLAB0.30
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
- Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall